Literature DB >> 9681496

Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation.

S E Damon1, L Maddison, J L Ware, S R Plymate.   

Abstract

Insulin-like growth factor (IGF) binding proteins (IGFBPs) have been shown to either inhibit or enhance the action of IGF, or act in an IGF-independent manner in the prostate. We have overexpressed the IGF-inhibitory IGFBP-4 in the malignant M12 prostate epithelial cell line to determine the effects on tumor formation and apoptosis. Overexpression was determined by Northern, Western immunoblot and Western radioligand blot analysis. IGF-induced proliferation was reduced in the IGFBP-4 transfected cells compared with control cells (P < or = 0.01). Colony formation in soft agar was significantly inhibited up to 14 days after plating in the IGFBP-4 transfected cells when compared with the M12 controls (P < or = 0.01): however, in the presence of des(1-3)IGF-I, there was no significant difference between the control and IGFBP-4 transfectants in colony formation in soft agar. Apoptosis in an IGFBP-4 transfected cell line was significantly increased in response to induction by 6-hydroxyurea compared with the control line. When injected s.c. into male athymic/nude mice, a marked delay was noted in tumor formation in animals receiving IGFBP-4 transfected cells (P < or = 0.01). Interestingly, IGFBP-2 protein levels were reduced in the conditioned media of all IGFBP-4 transfected cell cultures. These data indicate that an inhibitory IGFBP may significantly delay the growth of malignant prostate epithelial cells and enhance the sensitivity of these cells to apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9681496     DOI: 10.1210/endo.139.8.6150

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  22 in total

1.  Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue.

Authors:  Tanja Pascale Neuvians; Isabella Gashaw; Andrea Hasenfus; Axel Hacherhäcker; Elke Winterhager; Rainer Grobholz
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

Review 2.  Differing levels of testosterone and the prostate: a physiological interplay.

Authors:  S Larry Goldenberg; Anthony Koupparis; Michael E Robinson
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

3.  Endoglin regulates cancer-stromal cell interactions in prostate tumors.

Authors:  Diana Romero; Christine O'Neill; Aleksandra Terzic; Liangru Contois; Kira Young; Barbara A Conley; Raymond C Bergan; Peter C Brooks; Calvin P H Vary
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

4.  Insulin-like growth factor-binding protein 4 in children with acute lymphoblastic leukemia.

Authors:  Heike Wex; Dörte Ahrens; Bianka Hohmann; Antje Redlich; Uwe Mittler; Peter Vorwerk
Journal:  Int J Hematol       Date:  2005-08       Impact factor: 2.490

5.  Insulin-like growth factor binding protein-4 differentially inhibits growth factor-induced angiogenesis.

Authors:  Liangru W Contois; Desiree P Nugent; Jennifer M Caron; Alexandra Cretu; Eric Tweedie; Abebe Akalu; Leonard Liebes; Robert Friesel; Clifford Rosen; Calvin Vary; Peter C Brooks
Journal:  J Biol Chem       Date:  2011-12-01       Impact factor: 5.157

6.  Insulin like growth factor binding protein 4 promotes GBM progression and regulates key factors involved in EMT and invasion.

Authors:  V R Praveen Kumar; Priyanka Sehgal; Balram Thota; Shilpa Patil; Vani Santosh; Paturu Kondaiah
Journal:  J Neurooncol       Date:  2014-01-07       Impact factor: 4.130

7.  Proteomic profiling of androgen-independent prostate cancer cell lines reveals a role for protein S during the development of high grade and castration-resistant prostate cancer.

Authors:  Punit Saraon; Natasha Musrap; Daniela Cretu; George S Karagiannis; Ihor Batruch; Chris Smith; Andrei P Drabovich; Dominique Trudel; Theodorus van der Kwast; Colm Morrissey; Keith A Jarvi; Eleftherios P Diamandis
Journal:  J Biol Chem       Date:  2012-08-20       Impact factor: 5.157

8.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

9.  Massive hepatic apoptosis associated with TGF-beta1 activation after Fas ligand treatment of IGF binding protein-1-deficient mice.

Authors:  Julia I Leu; Mary Ann S Crissey; Rebecca Taub
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

10.  Expression of a protease-resistant insulin-like growth factor-binding protein-4 inhibits tumour growth in a murine model of breast cancer.

Authors:  A J Ryan; S Napoletano; P A Fitzpatrick; C A Currid; N C O'Sullivan; J H Harmey
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.